Esperion Therapeutics Inc. 's $1.25 billion sale to Pfizer Inc. in December 2003 was almost certainly a one-off. [See Deal] The biotech's most developed program was only in Phase II, yet the extraordinary price offered 1400% returns for the average private investor and a 55% premium to an already-high stock price. This is not the kind of deal that happens twice.
Still, when Esperion's ex-VP chemistry and technologies Jean-Louis Dasseux, PhD co-founded Cerenis Therapeutics SA in March 2005, he was...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?